The relationship between quantitative Plasmodium falciparum or P. vivax parasitemia and clinical illness has not been defined in Pakistan or in other areas where malaria transmission is not highly endemic. Standardized questionnaires were given to and physical examinations and parasitologic tests were performed in 8,941 subjects seen in outpatient clinics in 4 villages for 13 consecutive months in the Punjab region of Pakistan. The results, based on multivariable analysis, showed that a clinical diagnosis of malaria, a history of fever, rigors, headache, myalgia, elevated temperature, and a palpable spleen among children were all strongly associated with the presence and density of P. falciparum or P. vivax malaria in a monotonic dose-response fashion. The malaria attributable fraction of a clinical diagnosis of malaria, and the same symptoms and signs also increased with increasing P. falciparum and, to a lesser extent, P. vivax, parasitemia. Unlike in sub-Saharan Africa, clinical illness due to malaria often occurs in the Punjab among adolescents and adults and in patients with parasite densities less than 1,000/l. Clinical guidelines based upon parasitemia and symptomatology must be adjusted according to the intensity of transmission and be specific for each geographic area.
Morbidity and mortality have been strongly linked to
Plasmodium falciparum parasite density and guidelines have been introduced for etiologic classification of febrile illnesses and for therapeutic regimens based upon density of parasites in the blood. While P. falciparum is the predominant species in sub-Saharan Africa, where most of the studies comparing clinical illness with intensity of infection have been conducted, [1] [2] [3] [4] [5] [6] malaria in southern Asia and many other endemic areas is caused by both P. falciparum and P. vivax and is characterized by a much lower sporozoite inoculation rate. The relationship between parasite density and clinical illness in such an environment has not been defined as it has been in Africa. Also, the impact of increasing P. vivax parasite density on clinical disease has not been studied as rigorously as has P. falciparum.
Based on our experience with malaria in the Pakistani Punjab, we hypothesized that clinical disease with P. falciparum, in an environment where transmission is less intense, seasonal and both P. vivax and P. falciparum coexist, will occur at lower parasitemia levels and in a wider and older age compared with Africa. This is because protective immunity is expected to be slower to develop and less prevalent. Using an extensive clinical and parasitologic data set with multivariable statistical methods, we investigated the impact of increasing parasite density on clinical symptoms and signs of malaria. The prevalence and density of parasitemia in the Punjab is described broadly to provide the proper epidemiologic context, but has been described in greater detail in previous publications. [7] [8] [9] MATERIALS AND METHODS Study area and study population. Four villages were selected for close monitoring of the epidemiology of malaria. The villages are located in the Kasur District of the Pakistani province of Punjab, about 60 km south of Lahore near the market town of Bhai Pheru. Previous epidemiologic, entomologic, parasitologic, and clinical studies in this setting have shown that malaria is endemic, with seasonal fluctuations, rather than epidemic. The prevalence, particularly that of P. falciparum, was highest in October and November (37%) and the highest P. vivax parasite rate occurred during August (18%). The greatest prevalence of infection due to both species combined occurred in October and November (43%). 7, 8 However, the vectorial capacity of the local vector, Anopheles culicifacies, was very low and inhabitants of these communities would have been exposed to very few infectious bites each malaria season. 10, 11 Rice and wheat are the principal crops grown in this area and the fields are irrigated using water from table wells and canals. The flooded paddy fields and, during the rainy season from July to September, the standing ground water provide breeding sites for anopheline mosquitoes. The 4 villages (Khanke, Baghiana, Plair, and Deoki) are located on either side and within 20-200 meters of the Rohi irrigation drain. The water in this drain supplies potential breeding sites for anopheline mosquitoes throughout the year, even during the dry seasons. The populations of 3 of the 4 villages ranged from approximately 300 to 1,300 people. Khanke, the largest village, had 5,500 inhabitants.
Data collection. Clinical surveys. Outpatient clinics were held by 1-3 physicians and 3-5 paramedics, usually every two weeks, in each village. 7 Clinics were conducted for 13 months between March 1984 and March 1985. Every villager was eligible to visit the clinic. Each patient was registered, his or her house number and other personal data were recorded, and the patient's temperature was taken. The physician used a standard form listing the most common symptoms and signs. The accompanying adult, usually a parent or relative, was used to obtain demographic and clinical information for children less than 10 years of age. Physical examination was limited to the patient's area of complaint with the exception of children less than 10 years of age who had abdominal examinations for detection of splenic and hepatic enlargement. A clinical diagnosis was made by the physician and appropriate therapy was dispensed before the results of the Giemsa-stained blood films were known. Fingerprick thick and thin blood films were taken from every patient whether they complained of fever or not. The number of patients seen and blood films taken during each of these clinics usually ranged from 25 in the smallest village to 150 in the largest one. This study was approved by the University of Maryland Institutional Review Board. The Institutional Review Board (in 1984) did not require that informed consent be obtained from the subjects since only clinical pertinent information was collected. The questionnaires were used as outpatient data files and the fingerpricks were used to diagnose malaria. For the purpose of data analysis for publication, subjects were coded as numbers, not by names.
Processing of blood films. Thick and thin blood films were made on the same slide from all patients, regardless of symptoms, seen in the clinics. The thin film was fixed with methanol and the whole slide was stained for 30 min with 3% Giemsa diluted in a phosphate buffer solution, pH 7.2. The numbers of asexual and sexual stages of P. vivax and P. falciparum were counted against white blood cells (WBCs) in the same oil immersion field (1,000ϫ). The thick film was used for counting, but the diagnosis was confirmed from the thin film. Parasites were recorded per 500 WBCs with the exception of cases of high parasitemias (parasites as frequent as WBCs) when only 100-200 WBCs were counted. All blood films were examined for at least 15 min by an experienced technician before being recorded as negative. The density of parasitemia was estimated using 8,000 WBC/l of blood as a standard value. Thus, if 500 WBCs were counted, the number of parasites counted was multiplied by 16 to obtain the parasite density per microliter of blood.
Statistical methods. To present the transmission pattern of malaria in the 4 communities, malaria prevalence was expressed as the percentage of parasitemic patients among all patients seen in the outpatient clinics. Although this is not a true community prevalence of infection, this parasite rate was remarkably similar to the prevalence calculated from cross-sectional community surveys. 7 The prevalence of P. falciparum and P. vivax parasitemia was calculated across the following variables: village of residence, season, age, and gender. Prevalence odds ratios (ORs) and 95% confidence intervals (CIs) were constructed to examine differences in prevalence rates across these stratification variables using appropriate reference groups. Species-specific geometric mean parasite densities (with 95% CIs) were also calculated across these variables using the same reference groups. Analysis of variance was conducted using the log-transformed continuous parasite density data.
To assess the relationship between P. falciparum parasite density and clinical signs and symptoms of malaria, individuals with P. vivax or mixed infections were excluded. In the same way, individuals with P. falciparum infection (either alone or mixed) were excluded when P. vivax parasitemia was evaluated. Plasmodium falciparum-only and P. vivaxonly parasitemia densities were grouped into 4 strata: none (aparasitemic for both species), 1-999/l, 1,000-4,999/l, and Ն5,000/l. The prevalence of malarial signs and symptoms within the parasite density strata was calculated.
Multiple logistic regression modeling was used to estimate the associations between parasite density and various signs and symptoms of malaria. Age, village, and season were examined as effect modifiers and these potential confounders were controlled in the multivariable models. Parasitemia rates and densities did not vary significantly by gender; thus, this variable was not included in the regression models. For each sign and symptom examined, ORs and 95% CIs were computed for the 3 parasite density groups using the aparasitemic group as the reference category. A test for linear trend analysis was conducted by treating the parasitemia level dummy variables as a continuous score variable.
The malaria-attributable fraction (MAF) , or the proportion of individual symptoms and signs attributable to either P. falciparum or P. vivax malaria in this clinical setting was estimated using a model-based extension of the classic methods described by Smith and others, 12 which allowed for the control of potential confounding variables. This was done for the presence of individual symptoms and signs that were associated (P Ͻ 0.05) with parasitemia in the adjusted models; the approach works well because of the observed monotonic relationship between parasite density and the symptoms/signs of malaria in this data set.
The overall estimate of ( ϭ p(R Ϫ 1)/R) was calculated using only 2 categories (with/without parasitemia), where p is the proportion of parasitemic individuals who presented with the symptom or sign in question and R is the relative risk of the sign or symptom associated with the exposure. In this case, R is estimated by the adjusted OR of the symptom/sign in question for the parasitemic group (relative to the baseline aparasitemic group) derived from the fitted logistic regression model that simultaneously controls for potential confounding effects of village, age, and season.
Separate logistic regression models were also constructed to examine the parasite density-specific MAF j ( j ϭ p j (R j Ϫ 1)/R j ) associated with each of the 4 parasite density categories (j ϭ 1, 2, 3, and 4), where R j is the adjusted OR of the various symptoms/signs for the jth category, relative to the baseline category j ϭ 1, which is based upon observations on aparasitemic patients, and p j is the proportion of patients with the symptom or sign in question with parasites in the jth category.
In addition, for symptoms and signs for which there was important effect modification by age, strata-specific MAFs (Ͻ4 years, 4-12 years, Ն13 years) were calculated using stratified multiple logistic regression models. These a priori age groups were the most appropriate to demonstrate differences in response to infection and also to maximize the number of observations within each category.
Data analyses was performed using Epi-Info version 6.0 13 and SAS release 6.11 software. 14 
RESULTS
Parasite prevalence and density by village. Eight-thousand nine-hundred forty-one clinic contacts were available for analysis during the 13-month time period. The greatest number of individuals evaluated was at Khanke village (n ϭ 4,337) followed by Baghiana (n ϭ 2,201), Plair (n ϭ 1,705), and Deoki (n ϭ 698).
Plasmodium falciparum. Despite the fact that the 4 villages are quite close geographically and have similar ecologic habitats, there were considerable differences in their parasitemia rates (Table 1) . Using Khanke as the reference group, the OR for P. falciparum parasite prevalence was significantly increased in Deoki, Baghiana, and Plair. There was significant (P Ͻ 0.03) variation in P. falciparum mean parasite densities by village of residence. Specifically, the geometric mean densities were higher (P Ͻ 0.001) in Deoki than in Baghiana. Plasmodium vivax. The average prevalence of P. vivax infection showed less variation between villages than P. falciparum, although it was 40% higher (P Ͻ 0.05) in Baghiana than Khanke (Table 1) . No significant (P ϭ 0.38) variation in mean P. vivax parasite densities was observed between the 4 villages.
Parasite prevalence and density by season. Plasmodium falciparum. The prevalence of parasitemia showed considerable seasonal variation. The parasitemia rate ranged from 3.5% during July-August to 18.8% during clinic surveys held from September to December (Table 1) . Using JanuaryJune as the reference time period, the OR for the P. falciparum parasite rate was significantly higher during September-December and significantly lower during the July-August period. Plasmodium falciparum parasite densities also showed variation (P Ͻ 0.001) by season. Specifically, the geometric mean parasite density during the peak prevalence period, September-December, was much higher than during the rest of the year (Table 1) .
Plasmodium vivax. The P. vivax parasitemia rates also showed significant variation by season although to a lesser extent than P. falciparum (Table 1) . Plasmodium vivax prevalence was 20% higher during September-December and 60% higher in July-August than in January-June. Mean parasite densities varied to a lesser extent across the seasons than did P. falciparum but were still different (P ϭ 0.04; Table 1 ).
Parasite prevalence and density by age. Plasmodium falciparum. Prevalence of P. falciparum increased from 5% in children Ͻ2 years of age to 17% in those 13-17 years of age ( Figure 1 ). It decreased thereafter to a low of 6.6% among those Ն 40 years of age. Mean P. falciparum parasitemia levels were relatively stable at approximately 1,300/ l until the age of 18. There was a sharp increase in the mean parasitemia density in the 18-29-year-old age group (2,160/l) that was higher than either of the adjacent age groups (P Ͻ 0.05). Mean P. falciparum parasitemias decreased progressively thereafter ( Figure 1 ).
Plasmodium vivax. The peak prevalence (16-19%) of P. vivax was highest in those 2-7 years old, which was much earlier than that observed for P. falciparum ( Figure 1 ). By 13-17 years of age, P. vivax parasitemia prevalence was 5.8% and it progressively decreased to 2.2% in those Ն40 years of age ( Figure 1 ). Plasmodium vivax mean parasite densities were much lower than P. falciparum densities at all ages and, unlike P. falciparum, decreased with age from 976/l in those Ͻ2 years of age to 697/l in infants 2-3 years of age to Ͻ500/l in all older age groups ( Figure 1) .
Parasite density distribution. Plasmodium falciparum densities were higher than P. vivax densities as shown by the fact that only 36.2% of P. falciparum infections were Ͻ 500/l compared with 60.3% of P. vivax infections (Table  2) . Moreover, 24.6% of P. falciparum infections were in the highest density group (Ն5,000/l) compared with only 13.0% of P. vivax infections. The geometric mean densities were also consistently higher in each density category for P. falciparum compared with P. vivax.
Parasite density and clinical diagnosis of malaria. Despite the fact that 15.7% of the 7,179 aparasitemic patients were diagnosed with malaria, the density of parasitemia was strongly associated with a clinical diagnosis of malaria for both P. falciparum (Table 3) and P. vivax (Table 4) . Moreover, with each increasing level of parasite density, the OR for malaria diagnosis markedly increased in a linear doseresponse manner (P Ͻ 0.0001, by test for trend); 77.5% and 69.4% of patients with P. falciparum and P. vivax parasite densities Ն5,000/l were diagnosed and treated for malaria. The association of a clinical diagnosis of malaria and P. falciparum density was stronger than that for P. vivax as demonstrated by the higher ORs observed for each parasite density category.
The MAF of diagnosed clinical malaria also increased with increasing P. falciparum parasite density, and the attributable fraction associated with any parasitemia was 22.1% (Table 5 ). For P. vivax, the overall MAF was substantially lower (12.3%) and relatively constant over the parasite density strata (Table 6) .
Effect modification of the association between clinical malaria and P. falciparum parasite densities by age was also observed and is shown in Table 7 . While a significant trend of increasing ORs for clinical malaria over all 3 age strata is still observed, the strength of the observed crude and density-specific associations were weaker in children less than 4 years of age than the older age strata. In a similar fashion, the attributable fractions of clinical malaria was lower in those Ͻ4 years old (11.8%) than in those 4-12 years old (24.9%) and those Ն13 years old (23.1%). No important effect modification by age was observed between clinical malaria and P. vivax parasite density.
Parasite density and symptoms of malaria. History of fever. A history of fever was strongly associated with both P. falciparum and P. vivax parasitemia. For both P. falciparum and P. vivax, even parasite densities Ͻ1,000/l were associated with a significantly increased risk of a history of fever (Tables 3 and 4) . For both species, a strong linear doseresponse relationship was observed in which the risk of reporting a history of fever increased with increasing levels of parasite density (P Ͻ 0.0001); 81.9% and 69.4%, respectively, of those with P. falciparum and P. vivax parasite densities Ն5,000/l reported a history of fever. The strength of the association between parasite density and a history of fever was stronger for P. falciparum than P. vivax in all 3 density categories.
Similarly, the MAF for a report of recent fever was higher for P. falciparum (17.5%) than P. vivax (7.4%) and increased with increasing parasite density for both species (Tables 5 and 6). The strength of this association between P. falciparum parasitemia and a history of fever increased with age (Table 7) . This was also reflected in the higher overall and density-specific strata MAFs found in the 2 older age group (Table 7) . The estimated MAFs due to P. falciparum for patients Ͻ4 years, 4-12 years, and Ն13 years of age were 10.9%, 18.5%, and 19.9%, respectively. There was no effect modification of the association of P. vivax parasitemia with a history of fever.
Rigors. Although a rarer complaint, rigors were also strongly associated with both P. falciparum and P. vivax parasite densities (Tables 3 and 4) . At all parasite density § Results for children Ͻ10 years of age only. Sample sizes for children Ͻ10 years of age by parasitemia group are negative, n ϭ 3,129; 1-999/l, n ϭ 208; 1,000-4,999/l, n ϭ 113; Ն5,000/l, n ϭ 127. levels, for both species, there was a significantly increased risk for rigors. For both malarial species, the strength of the association between the complaint of rigors increased with increasing category of density level in a statistically significant linear dose-response manner; 62.6% and 42.9%, respectively, of those with P. falciparum and P. vivax parasite densities Ն5,000/l reported a history of rigors. The strength of the association between density of parasitemia and presence of rigors was greater for P. falciparum than for P. vivax in all 3 parasitemia categories, but even parasitemia levels Ͻ1,000/l were significantly associated with rigors for both malarial species.
The attributable risk of malaria observed for the presence of rigors was higher than any other single symptom studied for both parasite species (Tables 5 and 6 ) although, predictably, it was higher for P. falciparum (26.4%) than for P. vivax (10.9%). The MAF increased over increasing parasite density for both species. Age was also found to be an important effect modifier for P. falciparum malaria. As shown in Table 7 , the presence of rigors was significantly associated with parasite density in a dose-response manner and was statistically significant in even the lowest parasite density stratum for all ages. However, the strength of this association increased as a function of age. In addition, the MAF was substantially higher among patients 4-12 years (28.2%) and Ն13 years (26.0%) of age than among children Ͻ4 years of age (18.6%).
Headache. Complaint of headache was associated with both P. falciparum and P. vivax parasitemia (Tables 3 and  4 ). For P. falciparum, even density levels Ͻ1,000/l were significantly associated with an increased odds of headache and strength of the association increased in a linear doseresponse manner in the 1,000-4,999/l and Ն5,000/l density categories. For P. vivax infection, only among individuals with parasite densities Ն5,000/ul was the relationship statistically significant.
The estimated MAF for headaches was greater for P. falciparum (14.0%) than for P. vivax (3.9%), and a dose-response relationship occurred with P. falciparum as MAF estimates increased with increasing parasitemia densities (Table 5). No such pattern was observed for P. vivax (Table 6) .
Nausea/vomiting/anorexia. These gastrointestinal symptoms were associated with P. falciparum parasitemia in the lowest density level and P. vivax density levels Ն1,000/l. § Results for children Ͻ10 years of age only. Sample sizes for children Ͻ10 years of age by parasitemia group are negative, n ϭ 3,129; 1-999/l, n ϭ 384; 1,000-4,999/l, n ϭ 98; Ն5,000/l, n ϭ 82. For both species, a significant dose-response relationship was observed (Tables 3 and 4) , although the strength of this association was greater for P. falciparum than P. vivax. Similarly, the MAF increased with increasing parasite density for both malarial species, but was substantially higher for P. falciparum (21.1%; Table 5 ) than for P. vivax (6.2%; Table  6 ).
Myalgia. The risk of myalgia was associated with P. falciparum parasite densities Ն1,000 parasites/l (Table 3) , but for P. vivax a significant relationship was observed only for densities Ն5,000/l (Table 4) . A significant trend was observed in which the risk of myalgia increased with increasing density for P. falciparum but not P. vivax. In the case of the latter, the association between any parasitemia and the report of myalgia was not statistically significant.
For P. falciparum, the excess risk of malaria associated with myalgia increased with increasing parasitemia densities and the overall MAF was estimated at 9.9% (Table 5) .
Weakness/fatigue. Complaints of weakness and/or fatigue were only significantly associated with P. falciparum parasite densities Ն5,000/l ( Table 3 ). The density-specific MAF was also highest in this highest density category (2.6%), but the overall MAF was only 4.4%. For P. vivax, parasite density levels were not significantly associated with risk for weakness/fatigue at any of the parasite density levels and no significant trend was observed (Table 4) .
Dizziness/light-headedness. Although it was a rare complaint, dizziness and/or lightheadedness significantly increased in all P. falciparum density categories examined, and a significant trend was observed of increasing strength of association with increasing parasitemia levels ( Table 3) . The MAF was highest in the highest parasite density category and the overall MAF was 18.3%. On the other hand, only P. vivax parasite densities Ն5,000/l were associated with dizziness and/or lightheadedness, although only 3.1% of patients within this density category experienced these symptoms (Table 4) .
Absence of cough. Both P. falciparum and P. vivax infections were significantly associated with the absence of a complaint of cough. For P. falciparum, parasitemia levels Ն1,000/l were significantly associated with the absence of cough, and a significant trend (P Ͻ 0.0001) was observed of increasing ORs for the absence of cough as parasitemia density levels increased (Table 3 ). For P. vivax, absence of cough was significantly more prevalent among patients with parasite densities Ͻ1,000/l and Ն5,000/l than aparasitemic patients, and a border-line significant linear trend was observed in which increasing densities of P. vivax parasitemia were associated with decreased ORs for cough ( Table 4) .
Absence of diarrhea/dysentery. The absence of diarrhea/ dysentery was associated with both P. falciparum (OR ϭ 1.5, 95% CI ϭ 1.1-2.0) and P. vivax (OR ϭ 1.4, 95% CI ϭ 1.1-1.8) parasitemia. However, these relationships were weak and were only significant when stratified by parasitemia levels in the group with the lowest P. falciparum parasite density strata (Tables 3 and 4) .
Other symptoms. Prevalence of backache was low (3.5%) among aparasitemic patients and did not increase significantly in any parasite density categories for either P. falciparum (Table 3) or P. vivax (Table 4) . Abdominal pain was not associated with either P. falciparum or P. vivax parasitemia.
Parasite density and signs of malaria. Elevated temperature. The density of parasitemia of both P. falciparum (Table 3) and P. vivax (Table 4) was significantly associated with a recorded temperature Ն38.0ЊC. Also, a trend (P Ͻ 0.0001) was observed in which the magnitude of the association increased as the level of parasite density increased; patients with P. falciparum and P. vivax parasite densities Ն5,000/l had a 40.0% and 41.8% chance, respectively, of having an elevated temperature recorded at the time of their clinic visit. The observed OR associated with each density level were higher for P. falciparum than for P. vivax. For P. falciparum, the proportion of fever cases that was attributable to malaria increased as a function of parasite density and was 13.0% in the Ն5,000/l category. The overall P. falciparum MAF for elevated temperature was 19.3%. Interestingly, age was an effect modifier of the association between elevated temperature and P. falciparum parasite density (Table 7) . This can be seen in two ways. First, the ORs of an elevated temperature's association with any parasitemia, and at all levels of parasite density, increased with age. Second, the MAFs for elevated temperature increased as a function of age in both an overall sense and in all parasitemia level strata. The overall MAF was 6.4% in those Ͻ4 years old, 23.3% in those 4-12 years old, and 29.6% in those Ն13 years old. Splenomegaly. Splenic enlargement was consistently measured only in children less than 10 years of age and was detected in 4.7% of aparasitemic patients. However, its prevalence was significantly increased among children at all levels of P. falciparum (Table 3) or P. vivax parasitemia (Table  4) . A trend was observed in which the prevalence of splenomegaly increased (P Ͻ 0.0001) with each increasing density level of P. falciparum and P. vivax infection; 32.3% and 19.5%, respectively, of those with P. falciparum and P. vivax parasite densities Ն5,000/l had splenomegaly. The association between P. falciparum parasite density and splenomegaly was stronger than that observed for P. vivax. The highest density-specific and overall MAFs were found for splenomegaly for both malarial species. For P. falciparum, the overall MAF was 52.1% (Table 5 ) and for P. vivax, it was 19.8%. No important effect modification of these associations were observed when the relationships were compared between children Ͻ4 years and Ն5 years of age.
Hepatomegaly. The risk of hepatomegaly was significantly increased among children Ͻ10 years of age with a P. falciparum density Ͻ1,000/l, but it was not associated with either P. falciparum (Table 3) or P. vivax (Table 4) parasitemia in a dose-response fashion. Despite the low prevalence of this sign, the P. falciparum-attributable fraction associated with it was fairly high, particularly in the Ͻ1,000/l category (18.3%), and the overall MAF for hepatomegaly was 29.4%. There was no estimated malaria-attributable hepatomegaly associated with P. vivax parasitemia.
DISCUSSION
Our carefully collected clinical and parasitologic data from almost 9,000 patient encounters over 13 consecutive months in four rural communities in Pakistani Punjab allowed for the examination of 1) species-specific parasite prevalence and density over the important stratification variables, village of residence, season, and age, and 2) the relationship between species-specific parasite density and clinical symptoms and signs of malaria.
The highest prevalence and density of P. falciparum malaria was observed during September through December (Table 1) at the end of rainy season. The P. vivax infections predominated earlier in the transmission season in July through August after the rains begin, but lower mean parasite densities were fairly constant over the year ( Table 1) . The early predominance of P. vivax is believed to be related to the greater ability of P. vivax to produce gametocytemia when conditions become favorable during the early rains, and a lower critical temperature for sporogony. 7 Suppression of P. vivax by P. falciparum has been hypothesized to account for the relative predominance of P. falciparum in the late season because of its greater virulence in humans. 8 The exact mechanism is unknown but it resembles the relationship between P. malariae and P. falciparum in sub-Saharan Africa, where the former increases in prevalence during seasons of low transmission. 15 Our results show that individuals develop immunity to P. vivax at an earlier age than P. falciparum ( Figure 1 ) and that resistance, or immunity, to P. vivax evolves after 3 or 4 months each transmission season. 8 The earlier development of clinical immunity for P. vivax than P. falciparum has been documented in other areas of the world. [16] [17] [18] Most geographic areas where malaria is transmitted have much lower levels of transmission than sub-Saharan Africa and Papua New Guinea. Inhabitants of these other areas may be bitten by only 1 infected mosquito per year, 11 not the 1 or 2 per night sometimes reported from highly endemic areas. 4, 19 It is also well known that in areas of low malaria transmission, the natural history of falciparum malaria is different. For instance, because of the delayed development of immunity to infection and protection from disease, clinical illness associated with P. falciparum parasitemia occurs in adolescents and adults as well as in young children, illness often occurs at lower levels of parasitemia, and the severity of clinical illness may be less except during epidemics, since both falciparum malaria immunity and morbidity and mortality are increased by multiple and repeated exposures to mosquitoes infected with P. falciparum. 4, 5, 15 Evaluations of the use of insecticide-treated bed nets, which quantitatively reduce exposures to malaria sporozoites and markedly reduce malaria morbidity and mortality but have a lesser effect on the incidence of infection, have provided support for this hypothesis. 20 There was a substantial proportion of asymptomatic malarial infections among our study subjects despite the fact that the study was based in a clinical setting, albeit not in sick hospitalized patients. For example, among P. falciparum-parasitemic patients, only 55% had a history of fever within the past 2 weeks and only 20% had an elevated temperature when clinically evaluated (Table 3) . This is lower than other studies from Malaysia and India in which 60-75% of falciparum-positive patients of all ages had fever, respectively. 21, 22 For P. vivax, even a greater proportion of parasitemic patients were asymptomatic as shown by the fact only 41% had a history of fever and 17% had a recorded fever at the time of the examination ( Table 4 ). The absence of symptoms in many parasitemic inhabitants of communities endemic for malaria is well known. 12, 15 In fact, investigators reporting results from sub-Saharan Africa generally only include high densities of P. falciparum parasitemia (adjusted for age) as part of the definition for malaria disease. 6, [23] [24] [25] Nevertheless, the results of adjusted multiple logistic regression models showed that a clinical diagnosis of malaria by the examining physician: a history of fever, rigors, headache, and an elevated temperature or a palpable spleen in children were all highly associated with the presence of malaria parasites and the density of parasites in the blood in a monotonic dose-response manner. This association was present with either P. falciparum or P. vivax infections although the strength of association was greater with the former. Even P. falciparum, and to a lesser extent P. vivax, parasite levels less than 1,000/l of blood significantly increased the odds of a clinical diagnosis of malaria and the symptoms and signs associated with malaria. The association of gastrointestinal symptoms with P. falciparum, and not P. vivax, may be the result of sludging of parasitized erythrocytes in the villous capillaries causing edema and increased permeability of the intestinal mucosa, which occurs in the former but not the latter. 26 The association between P. falciparum density and dizziness/lightheadedness may be explained by increased vascular permeability with a decreased effective blood volume. 27 Since these pathophysiologic changes occurred in falciparum, but not vivax, malaria, it is not surprising that we demonstrated an association only between them and the former species. However, it is incorrect to assume that these symptoms do not occur during vivax infections, particularly in nonimmune persons.
Since our subjects were patients who sought medical assistance in temporary community clinics for a variety of different illnesses 7, 8 there were competing causes of morbidity; many patients had nonspecific upper respiratory infections or diarrhea, particularly during the dry season when malaria transmission rates are very low. 7, 8, 11 We believe this accounts for the negative correlation between both cough and diarrhea with malarial parasitemia.
The strength of the linear dose-response relationship of symptomatology with P. falciparum parasite density among our subjects is greater than that found in most other publications, which have been based upon people living in areas with a much higher level of transmission than in the Pakistani Punjab. [3] [4] [5] [6] 24, 27, 28 In addition, clinical illness compatible with malaria in our subjects was associated with lower levels of parasitemia than was noted in most of these reports. Whereas clinical illness is often not associated with densities of P. falciparum parasitemias less than 10,000/l in Africa 23 or Papua New Guinea, 29 patients in Pakistan (and possibly other areas with low sporozoite inoculation rates) frequently have malaria morbidity associated with less than 1,000 parasites/l. Another example of this relationship was reported from Vanuatu where densities of both P. falciparum and P. vivax less than 1,000/l were associated with clinical malaria. 16 A non-monotonic relationship between fever risk and parasite density has frequently been observed in highly endemic areas where prevalence rates are very high. 12, [30] [31] [32] [33] In these area, low parasite densities are associated with a decreased risk for fever, which is believed to result from an inhibitory effect of non-malarial infections on malaria parasites. 12 No evidence for such a phenomenon was observed in our study because even low-density parasitemia was associated with an increased risk for fever and other malariarelated morbidity.
The relationship between increasing P. falciparum parasitemia levels and fever has been previously reported from studies in sub-Saharan Africa and Papua New Guinea among children. 1, [2] [3] [4] [5] [23] [24] [25] 28, 34 More limited results from adolescents and adults from these areas have been mixed. Some reported that adults develop clinical symptoms of malaria at lower levels of parasitemia than children. 6, 23, 28, 29 However, Petersen and others 34 found no correlation between history of fever and chills, headache, body and joint pain, and elevated body temperature and parasitemia levels among 121 Liberian adults. While the results of our study showed no important differences in the association between various clinical signs or reported symptoms among patients with P. vivax infection, age was an effect modifier for P. falciparum parasitemia. As age increased, so did the strength of the absolute (any parasitemia) and the linear dose-response relationship with key clinical signs and symptoms (Table 7) . Also, in children less than 4 years of age, the minimal parasite density that was associated with a clinical diagnosis of malaria or an elevated temperature was greater than in the older age groups. This finding is opposite from that observed in holoendemic areas of Africa where anti-parasite immunity developed with age. 23, 25, 35 The overall and density-specific MAFs were uniformly higher for P. falciparum than P. vivax malaria, which corroborates our finding a greater strength of the association between morbidity and the former malarial species. Greenwood and others also found the population attributable fraction for fever was much higher for P. falciparum than P. malariae in a community-based study of 3,000 children in The Gambia. 1 Illness caused by malaria is less predominant in communities such as the Pakistani Punjab, where transmission is hypoendemic rather than holoendemic as in sub-Saharan Africa and Papua New Guinea. 7, 15 This was reflected in the fact that the estimated fraction of fever cases attributable to P. falciparum in our study was lower than that reported from a highly endemic area of Papua New Guinea in which 37% of 736 of presumptive cases of malaria, diagnosed principally on the basis of a history of fever, were estimated to be attributable to P. falciparum infection. Among children in The Gambia, Greenwood and others estimated that P. falciparum is responsible for 40-50% of episodes of fever. 1 A community-based study in Tanzania 36 reported estimated MAFs for fever for children Ͻ1, 1-4, and 5-9 years of age to be 45%, 32%, and 13%, respectively. Among adolescents and adults, there was no malaria-attributable morbidity associated with fever. In our study, age modified the estimated P. falciparum-related MAFs associated with a history of fever, rigors, a clinical diagnosis of malaria, and elevated temperature in the opposite direction of that observed in Tanzania (Table 7) . This further demonstrates the delayed development of immunity and the greater risk of clinical illness in adolescents and adults with parasitemia in the Pakistani Punjab than in holoendemic Africa and Papua New Guinea.
Since the natural history of malaria is highly influenced by the level of transmission, any effort to set universal arbitrary guidelines for the diagnosis of malaria based upon the density of parasitemia must be viewed with caution. They must be specific for each geographic area, and in the case where malaria transmission is seasonal, they must be adjusted to the seasonal level of transmission.
